Compare Ascendis Pharma A/S (ASND) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs D Wave Quantum Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while D Wave Quantum Inc trades at $19.72 (market cap $7.44B). The key difference: Ascendis Pharma A/S is far larger — about 2.4× D Wave Quantum Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ASND | QBTS | |
|---|---|---|
Market Cap | $17.74B | $7.44B |
Sector | Health | Technology |
52-Week High | $277.18 | $44.78 |
52-Week Low | $163.32 | $12.98 |
Enterprise Value | $18.11B | $6.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
D-Wave Quantum (QBTS) trades at $20.08, down 5.1% today amid bearish technical signals. The stock shows extreme valuation metrics with P/S of 551.27 and negative profitability, though analyst consensus remains unanimously bullish with a $39.86 price target representing 99% upside. Recent IDC MarketScape recognition and government grants highlight technological progress, but substantial cash burn and negative margins pose fundamental challenges.
While analyst optimism and quantum computing's long-term potential offer speculative appeal, QBTS faces significant execution risks with negative earnings, high cash burn, and competitive threats. The stock's current technical weakness near key support at $20 suggests near-term pressure, making it suitable only for risk-tolerant investors betting on quantum commercialization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
